Via appoints new VP; $20M Amgen verdict; WIPO FRAND report; Centripetal PTAB loss; Nokia-Acer withdrawal

1) Free: Via Licensing Alliance taps former TiVo, Technicolor executive to lead on licensing and strategy

Patrick Zhang has been appointed to the newly created role at a time when Via is looking to expand existing programs while launching into new areas.

2) Premium: Amgen must pay $20.2 million in damages over antibody patent infringement: District of Delaware jury

Following a trial in the United States District Court for the District of Delaware last week, a jury has found that Amgen’s subsidiary Teneobio has infringed one of competitor Harbour Antibodies’s antibody-related patents and owes over $20 million in damages.

3) Premium: PTAB invalidates final Centripetal patent tied to vacated $1.9 billion Cisco verdict

The PTAB on remand found several of the patent-at-issue’s claims obvious over a single prior art reference, ruling that even credible evidence of copying by Cisco couldn’t overcome a “strong case of obviousness” where the prior art was “essentially anticipatory”.

4) Premium but free summary: WIPO report endorses complementary use of FRAND valuation methodologies

WIPO’s new report on FRAND valuation rejects a one-size-fits-all approach to SEP licensing disputes. Instead, it argues that comparable-license, bottom-up, and top-down methodologies should be viewed as complementary tools for assessing whether licensing terms are fair, reasonable, and non-discriminatory.

5) LinkedIn: Nokia, Acer drop UPC case

This is just one case, but there could be a settlement.